nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—ABCB1—colon cancer	0.23	1	CbGaD
Ezetimibe—ABCC3—Fluorouracil—colon cancer	0.0768	0.139	CbGbCtD
Ezetimibe—ABCC3—Vincristine—colon cancer	0.0699	0.127	CbGbCtD
Ezetimibe—UGT1A1—Irinotecan—colon cancer	0.0598	0.108	CbGbCtD
Ezetimibe—ABCC3—Methotrexate—colon cancer	0.0423	0.0767	CbGbCtD
Ezetimibe—SLCO1B1—Irinotecan—colon cancer	0.0414	0.075	CbGbCtD
Ezetimibe—ABCC2—Irinotecan—colon cancer	0.0364	0.0659	CbGbCtD
Ezetimibe—ABCG2—Irinotecan—colon cancer	0.0329	0.0596	CbGbCtD
Ezetimibe—ABCC2—Vincristine—colon cancer	0.0318	0.0576	CbGbCtD
Ezetimibe—ABCG2—Fluorouracil—colon cancer	0.0316	0.0572	CbGbCtD
Ezetimibe—ABCG2—Vincristine—colon cancer	0.0287	0.0521	CbGbCtD
Ezetimibe—SLCO1B1—Methotrexate—colon cancer	0.0219	0.0397	CbGbCtD
Ezetimibe—ABCC2—Methotrexate—colon cancer	0.0192	0.0349	CbGbCtD
Ezetimibe—ABCG2—Methotrexate—colon cancer	0.0174	0.0315	CbGbCtD
Ezetimibe—ABCB1—Irinotecan—colon cancer	0.0119	0.0215	CbGbCtD
Ezetimibe—ANPEP—bile—colon cancer	0.0105	0.104	CbGeAlD
Ezetimibe—ABCB1—Vincristine—colon cancer	0.0104	0.0188	CbGbCtD
Ezetimibe—ABCG5—gall bladder—colon cancer	0.00942	0.0939	CbGeAlD
Ezetimibe—ABCG8—gall bladder—colon cancer	0.0084	0.0837	CbGeAlD
Ezetimibe—CYP3A4—Irinotecan—colon cancer	0.0071	0.0129	CbGbCtD
Ezetimibe—ABCB1—Methotrexate—colon cancer	0.00627	0.0114	CbGbCtD
Ezetimibe—CYP3A4—Vincristine—colon cancer	0.00621	0.0112	CbGbCtD
Ezetimibe—ABCC2—bile—colon cancer	0.00416	0.0415	CbGeAlD
Ezetimibe—ABCG5—digestive system—colon cancer	0.00371	0.037	CbGeAlD
Ezetimibe—UGT2B15—gall bladder—colon cancer	0.00353	0.0351	CbGeAlD
Ezetimibe—NPC1L1—digestive system—colon cancer	0.00349	0.0347	CbGeAlD
Ezetimibe—ABCG8—digestive system—colon cancer	0.00331	0.0329	CbGeAlD
Ezetimibe—SOAT1—gall bladder—colon cancer	0.00303	0.0302	CbGeAlD
Ezetimibe—ANPEP—gall bladder—colon cancer	0.0029	0.0289	CbGeAlD
Ezetimibe—ABCG5—liver—colon cancer	0.00276	0.0275	CbGeAlD
Ezetimibe—NPC1L1—liver—colon cancer	0.0026	0.0259	CbGeAlD
Ezetimibe—ABCG8—liver—colon cancer	0.00246	0.0245	CbGeAlD
Ezetimibe—ANPEP—embryo—colon cancer	0.00184	0.0183	CbGeAlD
Ezetimibe—SOAT1—smooth muscle tissue—colon cancer	0.00151	0.0151	CbGeAlD
Ezetimibe—ANPEP—epithelium—colon cancer	0.0015	0.015	CbGeAlD
Ezetimibe—UGT1A3—digestive system—colon cancer	0.00148	0.0147	CbGeAlD
Ezetimibe—SOAT1—renal system—colon cancer	0.00146	0.0145	CbGeAlD
Ezetimibe—ANPEP—smooth muscle tissue—colon cancer	0.00145	0.0144	CbGeAlD
Ezetimibe—ABCC3—gall bladder—colon cancer	0.00145	0.0144	CbGeAlD
Ezetimibe—ANPEP—renal system—colon cancer	0.00139	0.0139	CbGeAlD
Ezetimibe—UGT2B15—digestive system—colon cancer	0.00139	0.0138	CbGeAlD
Ezetimibe—SOAT1—digestive system—colon cancer	0.00119	0.0119	CbGeAlD
Ezetimibe—ANPEP—lymphoid tissue—colon cancer	0.00116	0.0115	CbGeAlD
Ezetimibe—ANPEP—digestive system—colon cancer	0.00114	0.0114	CbGeAlD
Ezetimibe—SOAT1—bone marrow—colon cancer	0.0011	0.011	CbGeAlD
Ezetimibe—UGT1A3—liver—colon cancer	0.0011	0.011	CbGeAlD
Ezetimibe—ABCC2—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.00107	0.0227	CbGpPWpGaD
Ezetimibe—SOAT1—vagina—colon cancer	0.00105	0.0105	CbGeAlD
Ezetimibe—ANPEP—bone marrow—colon cancer	0.00105	0.0105	CbGeAlD
Ezetimibe—UGT2B15—liver—colon cancer	0.00103	0.0103	CbGeAlD
Ezetimibe—UGT2B7—renal system—colon cancer	0.00103	0.0103	CbGeAlD
Ezetimibe—ANPEP—vagina—colon cancer	0.00101	0.0101	CbGeAlD
Ezetimibe—SLCO1B1—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.001	0.0213	CbGpPWpGaD
Ezetimibe—UGT2B7—Metapathway biotransformation—CHST4—colon cancer	0.000938	0.02	CbGpPWpGaD
Ezetimibe—SOAT1—liver—colon cancer	0.00089	0.00886	CbGeAlD
Ezetimibe—UGT1A1—renal system—colon cancer	0.000879	0.00876	CbGeAlD
Ezetimibe—ANPEP—liver—colon cancer	0.000851	0.00848	CbGeAlD
Ezetimibe—UGT2B7—digestive system—colon cancer	0.000848	0.00845	CbGeAlD
Ezetimibe—ABCG2—Abacavir transport and metabolism—ABCB1—colon cancer	0.000775	0.0165	CbGpPWpGaD
Ezetimibe—UGT1A1—Metapathway biotransformation—CHST4—colon cancer	0.000762	0.0162	CbGpPWpGaD
Ezetimibe—ABCC3—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000735	0.0157	CbGpPWpGaD
Ezetimibe—SLCO1B1—renal system—colon cancer	0.000731	0.00729	CbGeAlD
Ezetimibe—UGT1A1—digestive system—colon cancer	0.000721	0.00718	CbGeAlD
Ezetimibe—ABCC3—renal system—colon cancer	0.000694	0.00692	CbGeAlD
Ezetimibe—SOAT1—lymph node—colon cancer	0.000682	0.0068	CbGeAlD
Ezetimibe—ANPEP—lymph node—colon cancer	0.000652	0.0065	CbGeAlD
Ezetimibe—NPC1L1—Metabolism—CA7—colon cancer	0.000634	0.0135	CbGpPWpGaD
Ezetimibe—UGT2B7—liver—colon cancer	0.000632	0.0063	CbGeAlD
Ezetimibe—SLCO1B1—digestive system—colon cancer	0.0006	0.00598	CbGeAlD
Ezetimibe—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000583	0.0124	CbGpPWpGaD
Ezetimibe—ABCC3—digestive system—colon cancer	0.000569	0.00567	CbGeAlD
Ezetimibe—ABCC2—renal system—colon cancer	0.000555	0.00553	CbGeAlD
Ezetimibe—SLCO1B1—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000547	0.0117	CbGpPWpGaD
Ezetimibe—UGT1A1—liver—colon cancer	0.000537	0.00535	CbGeAlD
Ezetimibe—UGT1A3—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000521	0.0111	CbGpPWpGaD
Ezetimibe—UGT1A3—Metapathway biotransformation—CHST5—colon cancer	0.000507	0.0108	CbGpPWpGaD
Ezetimibe—UGT1A1—Irinotecan Pathway—APC—colon cancer	0.000503	0.0107	CbGpPWpGaD
Ezetimibe—ABCC2—Irinotecan Pathway—APC—colon cancer	0.000491	0.0105	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—CA7—colon cancer	0.000481	0.0102	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—CA7—colon cancer	0.000463	0.00985	CbGpPWpGaD
Ezetimibe—SLCO1B1—Irinotecan Pathway—APC—colon cancer	0.000461	0.00982	CbGpPWpGaD
Ezetimibe—ABCC2—digestive system—colon cancer	0.000455	0.00453	CbGeAlD
Ezetimibe—SLCO1B1—liver—colon cancer	0.000447	0.00445	CbGeAlD
Ezetimibe—ABCC3—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000443	0.00944	CbGpPWpGaD
Ezetimibe—ABCB1—blood vessel—colon cancer	0.000442	0.0044	CbGeAlD
Ezetimibe—UGT2B7—Metapathway biotransformation—CHST5—colon cancer	0.000431	0.00918	CbGpPWpGaD
Ezetimibe—ABCG2—Irinotecan Pathway—APC—colon cancer	0.000427	0.00909	CbGpPWpGaD
Ezetimibe—ABCC3—Fluoropyrimidine Activity—TYMS—colon cancer	0.000425	0.00905	CbGpPWpGaD
Ezetimibe—ANPEP—Cardiac Progenitor Differentiation—TGFB1—colon cancer	0.000424	0.00904	CbGpPWpGaD
Ezetimibe—ABCC3—liver—colon cancer	0.000424	0.00423	CbGeAlD
Ezetimibe—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000422	0.00899	CbGpPWpGaD
Ezetimibe—ANPEP—C-MYB transcription factor network—PTGS2—colon cancer	0.000406	0.00865	CbGpPWpGaD
Ezetimibe—ABCC3—ABC-family proteins mediated transport—ABCB1—colon cancer	0.000403	0.00859	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—CHST5—colon cancer	0.000384	0.00818	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—ODC1—colon cancer	0.000384	0.00818	CbGpPWpGaD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000369	0.00786	CbGpPWpGaD
Ezetimibe—ANPEP—C-MYB transcription factor network—CCND1—colon cancer	0.000367	0.00782	CbGpPWpGaD
Ezetimibe—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.00036	0.00767	CbGpPWpGaD
Ezetimibe—ANPEP—Peptide hormone metabolism—CTNNB1—colon cancer	0.00036	0.00767	CbGpPWpGaD
Ezetimibe—Hot flush—Capecitabine—colon cancer	0.000356	0.00501	CcSEcCtD
Ezetimibe—ANPEP—C-MYB transcription factor network—CDKN1A—colon cancer	0.000355	0.00756	CbGpPWpGaD
Ezetimibe—Amnesia—Capecitabine—colon cancer	0.000354	0.00499	CcSEcCtD
Ezetimibe—Menopausal symptoms—Capecitabine—colon cancer	0.000353	0.00497	CcSEcCtD
Ezetimibe—Inflammation—Methotrexate—colon cancer	0.000352	0.00495	CcSEcCtD
Ezetimibe—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000351	0.00748	CbGpPWpGaD
Ezetimibe—UGT1A1—Metapathway biotransformation—CHST5—colon cancer	0.00035	0.00746	CbGpPWpGaD
Ezetimibe—Vasculitis—Methotrexate—colon cancer	0.00035	0.00492	CcSEcCtD
Ezetimibe—Connective tissue disorder—Vincristine—colon cancer	0.000347	0.00489	CcSEcCtD
Ezetimibe—ANPEP—Metabolism of proteins—CDX2—colon cancer	0.000345	0.00735	CbGpPWpGaD
Ezetimibe—Sinusitis—Fluorouracil—colon cancer	0.000344	0.00485	CcSEcCtD
Ezetimibe—Arthritis—Capecitabine—colon cancer	0.000342	0.00482	CcSEcCtD
Ezetimibe—ABCC2—liver—colon cancer	0.000339	0.00338	CbGeAlD
Ezetimibe—Connective tissue disorder—Irinotecan—colon cancer	0.000338	0.00476	CcSEcCtD
Ezetimibe—ANPEP—C-MYB transcription factor network—EP300—colon cancer	0.000338	0.0072	CbGpPWpGaD
Ezetimibe—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000335	0.00713	CbGpPWpGaD
Ezetimibe—Pain in extremity—Capecitabine—colon cancer	0.000333	0.00469	CcSEcCtD
Ezetimibe—Pharyngitis—Fluorouracil—colon cancer	0.000327	0.0046	CcSEcCtD
Ezetimibe—ABCC3—lymph node—colon cancer	0.000325	0.00324	CbGeAlD
Ezetimibe—Angiopathy—Vincristine—colon cancer	0.00032	0.00451	CcSEcCtD
Ezetimibe—ABCC2—ABC-family proteins mediated transport—ABCB1—colon cancer	0.00032	0.00681	CbGpPWpGaD
Ezetimibe—Flushing—Irinotecan—colon cancer	0.000319	0.00449	CcSEcCtD
Ezetimibe—Mediastinal disorder—Vincristine—colon cancer	0.000318	0.00448	CcSEcCtD
Ezetimibe—ANPEP—C-MYB transcription factor network—NRAS—colon cancer	0.000316	0.00673	CbGpPWpGaD
Ezetimibe—Alopecia—Vincristine—colon cancer	0.000312	0.00439	CcSEcCtD
Ezetimibe—Angiopathy—Irinotecan—colon cancer	0.000312	0.00439	CcSEcCtD
Ezetimibe—Immune system disorder—Irinotecan—colon cancer	0.000311	0.00437	CcSEcCtD
Ezetimibe—Mediastinal disorder—Irinotecan—colon cancer	0.00031	0.00436	CcSEcCtD
Ezetimibe—Mental disorder—Vincristine—colon cancer	0.000309	0.00436	CcSEcCtD
Ezetimibe—CYP3A4—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.000309	0.00657	CbGpPWpGaD
Ezetimibe—Liver function test abnormal—Capecitabine—colon cancer	0.000307	0.00433	CcSEcCtD
Ezetimibe—ABCG2—bone marrow—colon cancer	0.000306	0.00305	CbGeAlD
Ezetimibe—Alopecia—Irinotecan—colon cancer	0.000304	0.00428	CcSEcCtD
Ezetimibe—Breast disorder—Capecitabine—colon cancer	0.000301	0.00423	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.0003	0.00422	CcSEcCtD
Ezetimibe—Nasopharyngitis—Capecitabine—colon cancer	0.000297	0.00419	CcSEcCtD
Ezetimibe—Back pain—Vincristine—colon cancer	0.000297	0.00419	CcSEcCtD
Ezetimibe—Flatulence—Irinotecan—colon cancer	0.000295	0.00415	CcSEcCtD
Ezetimibe—Gastritis—Capecitabine—colon cancer	0.000294	0.00415	CcSEcCtD
Ezetimibe—ANPEP—C-MYB transcription factor network—MYC—colon cancer	0.000294	0.00627	CbGpPWpGaD
Ezetimibe—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000294	0.00626	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—MUC2—colon cancer	0.000293	0.00625	CbGpPWpGaD
Ezetimibe—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000293	0.00413	CcSEcCtD
Ezetimibe—Muscular weakness—Capecitabine—colon cancer	0.000293	0.00413	CcSEcCtD
Ezetimibe—ABCG2—vagina—colon cancer	0.000293	0.00292	CbGeAlD
Ezetimibe—ABCG2—Fluoropyrimidine Activity—TYMS—colon cancer	0.000293	0.00624	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—CHST5—colon cancer	0.000291	0.0062	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—ODC1—colon cancer	0.000291	0.0062	CbGpPWpGaD
Ezetimibe—Alopecia—Fluorouracil—colon cancer	0.000291	0.0041	CcSEcCtD
Ezetimibe—Back pain—Irinotecan—colon cancer	0.00029	0.00408	CcSEcCtD
Ezetimibe—Muscle spasms—Irinotecan—colon cancer	0.000288	0.00405	CcSEcCtD
Ezetimibe—Influenza—Capecitabine—colon cancer	0.000288	0.00405	CcSEcCtD
Ezetimibe—Erythema—Fluorouracil—colon cancer	0.000287	0.00404	CcSEcCtD
Ezetimibe—Anaemia—Vincristine—colon cancer	0.000284	0.004	CcSEcCtD
Ezetimibe—Photosensitivity—Methotrexate—colon cancer	0.000282	0.00397	CcSEcCtD
Ezetimibe—CYP3A4—renal system—colon cancer	0.000282	0.00281	CbGeAlD
Ezetimibe—ABCG5—Metabolism—ODC1—colon cancer	0.00028	0.00597	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—CHST5—colon cancer	0.00028	0.00597	CbGpPWpGaD
Ezetimibe—Ill-defined disorder—Irinotecan—colon cancer	0.000278	0.00391	CcSEcCtD
Ezetimibe—Anaemia—Irinotecan—colon cancer	0.000277	0.0039	CcSEcCtD
Ezetimibe—Hepatic failure—Methotrexate—colon cancer	0.000276	0.00388	CcSEcCtD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000274	0.00584	CbGpPWpGaD
Ezetimibe—ANPEP—C-MYB transcription factor network—KRAS—colon cancer	0.000272	0.00579	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—CA7—colon cancer	0.000271	0.00577	CbGpPWpGaD
Ezetimibe—Malaise—Irinotecan—colon cancer	0.00027	0.0038	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Capecitabine—colon cancer	0.000267	0.00376	CcSEcCtD
Ezetimibe—Hypertension—Vincristine—colon cancer	0.000265	0.00374	CcSEcCtD
Ezetimibe—Anaemia—Fluorouracil—colon cancer	0.000265	0.00373	CcSEcCtD
Ezetimibe—ABCB1—embryo—colon cancer	0.000263	0.00263	CbGeAlD
Ezetimibe—Photosensitivity reaction—Capecitabine—colon cancer	0.000262	0.0037	CcSEcCtD
Ezetimibe—Myalgia—Vincristine—colon cancer	0.000262	0.00369	CcSEcCtD
Ezetimibe—Cough—Irinotecan—colon cancer	0.000261	0.00368	CcSEcCtD
Ezetimibe—ABCC2—lymph node—colon cancer	0.00026	0.00259	CbGeAlD
Ezetimibe—Hypertension—Irinotecan—colon cancer	0.000258	0.00364	CcSEcCtD
Ezetimibe—Infestation—Capecitabine—colon cancer	0.000256	0.00361	CcSEcCtD
Ezetimibe—Infestation NOS—Capecitabine—colon cancer	0.000256	0.00361	CcSEcCtD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000255	0.00543	CbGpPWpGaD
Ezetimibe—Discomfort—Irinotecan—colon cancer	0.000252	0.00355	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Capecitabine—colon cancer	0.000251	0.00354	CcSEcCtD
Ezetimibe—Anaphylactic shock—Vincristine—colon cancer	0.000251	0.00353	CcSEcCtD
Ezetimibe—Jaundice—Capecitabine—colon cancer	0.00025	0.00352	CcSEcCtD
Ezetimibe—Infection—Vincristine—colon cancer	0.000249	0.00351	CcSEcCtD
Ezetimibe—ABCG2—liver—colon cancer	0.000247	0.00246	CbGeAlD
Ezetimibe—Confusional state—Irinotecan—colon cancer	0.000246	0.00347	CcSEcCtD
Ezetimibe—Nervous system disorder—Vincristine—colon cancer	0.000246	0.00346	CcSEcCtD
Ezetimibe—Thrombocytopenia—Vincristine—colon cancer	0.000246	0.00346	CcSEcCtD
Ezetimibe—Anaphylactic shock—Irinotecan—colon cancer	0.000244	0.00344	CcSEcCtD
Ezetimibe—Myalgia—Fluorouracil—colon cancer	0.000244	0.00344	CcSEcCtD
Ezetimibe—Chest pain—Fluorouracil—colon cancer	0.000244	0.00344	CcSEcCtD
Ezetimibe—Infection—Irinotecan—colon cancer	0.000243	0.00342	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Capecitabine—colon cancer	0.000242	0.00342	CcSEcCtD
Ezetimibe—Discomfort—Fluorouracil—colon cancer	0.000241	0.0034	CcSEcCtD
Ezetimibe—Nervous system disorder—Irinotecan—colon cancer	0.00024	0.00337	CcSEcCtD
Ezetimibe—Thrombocytopenia—Irinotecan—colon cancer	0.000239	0.00337	CcSEcCtD
Ezetimibe—Confusional state—Fluorouracil—colon cancer	0.000236	0.00332	CcSEcCtD
Ezetimibe—Anaphylactic shock—Fluorouracil—colon cancer	0.000234	0.0033	CcSEcCtD
Ezetimibe—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000233	0.00496	CbGpPWpGaD
Ezetimibe—Infection—Fluorouracil—colon cancer	0.000232	0.00327	CcSEcCtD
Ezetimibe—ANPEP—C-MYB transcription factor network—HRAS—colon cancer	0.000231	0.00492	CbGpPWpGaD
Ezetimibe—CYP3A4—digestive system—colon cancer	0.000231	0.0023	CbGeAlD
Ezetimibe—Hepatitis—Capecitabine—colon cancer	0.00023	0.00324	CcSEcCtD
Ezetimibe—Nervous system disorder—Fluorouracil—colon cancer	0.000229	0.00323	CcSEcCtD
Ezetimibe—Thrombocytopenia—Fluorouracil—colon cancer	0.000229	0.00323	CcSEcCtD
Ezetimibe—Liver function test abnormal—Methotrexate—colon cancer	0.000229	0.00322	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Vincristine—colon cancer	0.000229	0.00322	CcSEcCtD
Ezetimibe—Pharyngitis—Capecitabine—colon cancer	0.000228	0.00322	CcSEcCtD
Ezetimibe—Insomnia—Vincristine—colon cancer	0.000227	0.0032	CcSEcCtD
Ezetimibe—Oedema peripheral—Capecitabine—colon cancer	0.000227	0.00319	CcSEcCtD
Ezetimibe—Connective tissue disorder—Capecitabine—colon cancer	0.000226	0.00319	CcSEcCtD
Ezetimibe—Paraesthesia—Vincristine—colon cancer	0.000225	0.00317	CcSEcCtD
Ezetimibe—Breast disorder—Methotrexate—colon cancer	0.000224	0.00315	CcSEcCtD
Ezetimibe—Insomnia—Irinotecan—colon cancer	0.000221	0.00311	CcSEcCtD
Ezetimibe—Paraesthesia—Irinotecan—colon cancer	0.000219	0.00309	CcSEcCtD
Ezetimibe—Decreased appetite—Vincristine—colon cancer	0.000218	0.00307	CcSEcCtD
Ezetimibe—Dyspnoea—Irinotecan—colon cancer	0.000218	0.00307	CcSEcCtD
Ezetimibe—Erythema multiforme—Capecitabine—colon cancer	0.000218	0.00306	CcSEcCtD
Ezetimibe—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—colon cancer	0.000217	0.00463	CbGpPWpGaD
Ezetimibe—Gastrointestinal disorder—Vincristine—colon cancer	0.000217	0.00305	CcSEcCtD
Ezetimibe—Fatigue—Vincristine—colon cancer	0.000216	0.00305	CcSEcCtD
Ezetimibe—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	0.000215	0.00459	CbGpPWpGaD
Ezetimibe—Dyspepsia—Irinotecan—colon cancer	0.000215	0.00303	CcSEcCtD
Ezetimibe—ABCB1—epithelium—colon cancer	0.000215	0.00214	CbGeAlD
Ezetimibe—Pain—Vincristine—colon cancer	0.000215	0.00302	CcSEcCtD
Ezetimibe—Constipation—Vincristine—colon cancer	0.000215	0.00302	CcSEcCtD
Ezetimibe—Flushing—Capecitabine—colon cancer	0.000214	0.00301	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000213	0.003	CcSEcCtD
Ezetimibe—Decreased appetite—Irinotecan—colon cancer	0.000212	0.00299	CcSEcCtD
Ezetimibe—Eosinophilia—Methotrexate—colon cancer	0.000212	0.00298	CcSEcCtD
Ezetimibe—Insomnia—Fluorouracil—colon cancer	0.000212	0.00298	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Irinotecan—colon cancer	0.000211	0.00297	CcSEcCtD
Ezetimibe—Fatigue—Irinotecan—colon cancer	0.000211	0.00297	CcSEcCtD
Ezetimibe—Paraesthesia—Fluorouracil—colon cancer	0.00021	0.00296	CcSEcCtD
Ezetimibe—Pancreatitis—Methotrexate—colon cancer	0.00021	0.00296	CcSEcCtD
Ezetimibe—Constipation—Irinotecan—colon cancer	0.000209	0.00294	CcSEcCtD
Ezetimibe—Pain—Irinotecan—colon cancer	0.000209	0.00294	CcSEcCtD
Ezetimibe—Angiopathy—Capecitabine—colon cancer	0.000209	0.00294	CcSEcCtD
Ezetimibe—Dyspnoea—Fluorouracil—colon cancer	0.000209	0.00294	CcSEcCtD
Ezetimibe—Immune system disorder—Capecitabine—colon cancer	0.000208	0.00293	CcSEcCtD
Ezetimibe—Mediastinal disorder—Capecitabine—colon cancer	0.000207	0.00292	CcSEcCtD
Ezetimibe—Dyspepsia—Fluorouracil—colon cancer	0.000206	0.0029	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Vincristine—colon cancer	0.000205	0.00289	CcSEcCtD
Ezetimibe—Decreased appetite—Fluorouracil—colon cancer	0.000203	0.00286	CcSEcCtD
Ezetimibe—Alopecia—Capecitabine—colon cancer	0.000203	0.00286	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000202	0.00285	CcSEcCtD
Ezetimibe—Mental disorder—Capecitabine—colon cancer	0.000202	0.00284	CcSEcCtD
Ezetimibe—Feeling abnormal—Irinotecan—colon cancer	0.000201	0.00284	CcSEcCtD
Ezetimibe—Malnutrition—Capecitabine—colon cancer	0.0002	0.00282	CcSEcCtD
Ezetimibe—Erythema—Capecitabine—colon cancer	0.0002	0.00282	CcSEcCtD
Ezetimibe—Pain—Fluorouracil—colon cancer	0.0002	0.00282	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Irinotecan—colon cancer	0.0002	0.00281	CcSEcCtD
Ezetimibe—ABCB1—renal system—colon cancer	0.000199	0.00199	CbGeAlD
Ezetimibe—Upper respiratory tract infection—Methotrexate—colon cancer	0.000199	0.0028	CcSEcCtD
Ezetimibe—Abdominal pain—Vincristine—colon cancer	0.000198	0.00279	CcSEcCtD
Ezetimibe—Body temperature increased—Vincristine—colon cancer	0.000198	0.00279	CcSEcCtD
Ezetimibe—Flatulence—Capecitabine—colon cancer	0.000197	0.00278	CcSEcCtD
Ezetimibe—Erectile dysfunction—Methotrexate—colon cancer	0.000197	0.00278	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Methotrexate—colon cancer	0.000195	0.00275	CcSEcCtD
Ezetimibe—Back pain—Capecitabine—colon cancer	0.000194	0.00273	CcSEcCtD
Ezetimibe—Abdominal pain—Irinotecan—colon cancer	0.000193	0.00272	CcSEcCtD
Ezetimibe—Body temperature increased—Irinotecan—colon cancer	0.000193	0.00272	CcSEcCtD
Ezetimibe—Feeling abnormal—Fluorouracil—colon cancer	0.000193	0.00272	CcSEcCtD
Ezetimibe—Muscle spasms—Capecitabine—colon cancer	0.000193	0.00271	CcSEcCtD
Ezetimibe—Infestation NOS—Methotrexate—colon cancer	0.000191	0.00269	CcSEcCtD
Ezetimibe—Infestation—Methotrexate—colon cancer	0.000191	0.00269	CcSEcCtD
Ezetimibe—ABCG2—lymph node—colon cancer	0.000189	0.00189	CbGeAlD
Ezetimibe—Ill-defined disorder—Capecitabine—colon cancer	0.000186	0.00262	CcSEcCtD
Ezetimibe—Urticaria—Fluorouracil—colon cancer	0.000186	0.00262	CcSEcCtD
Ezetimibe—Anaemia—Capecitabine—colon cancer	0.000185	0.00261	CcSEcCtD
Ezetimibe—Body temperature increased—Fluorouracil—colon cancer	0.000185	0.00261	CcSEcCtD
Ezetimibe—Hypersensitivity—Vincristine—colon cancer	0.000185	0.0026	CcSEcCtD
Ezetimibe—Malaise—Capecitabine—colon cancer	0.000181	0.00254	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Methotrexate—colon cancer	0.00018	0.00254	CcSEcCtD
Ezetimibe—Hypersensitivity—Irinotecan—colon cancer	0.00018	0.00254	CcSEcCtD
Ezetimibe—Asthenia—Vincristine—colon cancer	0.00018	0.00254	CcSEcCtD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000177	0.00378	CbGpPWpGaD
Ezetimibe—Palpitations—Capecitabine—colon cancer	0.000177	0.00249	CcSEcCtD
Ezetimibe—Asthenia—Irinotecan—colon cancer	0.000175	0.00247	CcSEcCtD
Ezetimibe—Cough—Capecitabine—colon cancer	0.000175	0.00246	CcSEcCtD
Ezetimibe—Hypertension—Capecitabine—colon cancer	0.000173	0.00244	CcSEcCtD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000173	0.00368	CbGpPWpGaD
Ezetimibe—Hypersensitivity—Fluorouracil—colon cancer	0.000172	0.00243	CcSEcCtD
Ezetimibe—CYP3A4—liver—colon cancer	0.000172	0.00172	CbGeAlD
Ezetimibe—Diarrhoea—Vincristine—colon cancer	0.000172	0.00242	CcSEcCtD
Ezetimibe—Hepatitis—Methotrexate—colon cancer	0.000171	0.00241	CcSEcCtD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—ABCB1—colon cancer	0.000171	0.00365	CbGpPWpGaD
Ezetimibe—Arthralgia—Capecitabine—colon cancer	0.000171	0.0024	CcSEcCtD
Ezetimibe—Chest pain—Capecitabine—colon cancer	0.000171	0.0024	CcSEcCtD
Ezetimibe—Myalgia—Capecitabine—colon cancer	0.000171	0.0024	CcSEcCtD
Ezetimibe—Pharyngitis—Methotrexate—colon cancer	0.00017	0.00239	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000169	0.00239	CcSEcCtD
Ezetimibe—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000169	0.0036	CbGpPWpGaD
Ezetimibe—Discomfort—Capecitabine—colon cancer	0.000169	0.00237	CcSEcCtD
Ezetimibe—Diarrhoea—Irinotecan—colon cancer	0.000167	0.00235	CcSEcCtD
Ezetimibe—Dry mouth—Capecitabine—colon cancer	0.000167	0.00235	CcSEcCtD
Ezetimibe—Dizziness—Vincristine—colon cancer	0.000166	0.00234	CcSEcCtD
Ezetimibe—ABCB1—lymphoid tissue—colon cancer	0.000166	0.00165	CbGeAlD
Ezetimibe—Pruritus—Fluorouracil—colon cancer	0.000166	0.00233	CcSEcCtD
Ezetimibe—Confusional state—Capecitabine—colon cancer	0.000165	0.00232	CcSEcCtD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000164	0.0035	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—CHST5—colon cancer	0.000164	0.00349	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—ODC1—colon cancer	0.000164	0.00349	CbGpPWpGaD
Ezetimibe—ABCB1—digestive system—colon cancer	0.000164	0.00163	CbGeAlD
Ezetimibe—Infection—Capecitabine—colon cancer	0.000162	0.00229	CcSEcCtD
Ezetimibe—Erythema multiforme—Methotrexate—colon cancer	0.000162	0.00228	CcSEcCtD
Ezetimibe—Dizziness—Irinotecan—colon cancer	0.000162	0.00228	CcSEcCtD
Ezetimibe—Nervous system disorder—Capecitabine—colon cancer	0.00016	0.00226	CcSEcCtD
Ezetimibe—Diarrhoea—Fluorouracil—colon cancer	0.00016	0.00225	CcSEcCtD
Ezetimibe—Thrombocytopenia—Capecitabine—colon cancer	0.00016	0.00225	CcSEcCtD
Ezetimibe—Vomiting—Vincristine—colon cancer	0.000159	0.00225	CcSEcCtD
Ezetimibe—Skin disorder—Capecitabine—colon cancer	0.000159	0.00224	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000159	0.00338	CbGpPWpGaD
Ezetimibe—Rash—Vincristine—colon cancer	0.000158	0.00223	CcSEcCtD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000158	0.00337	CbGpPWpGaD
Ezetimibe—Dermatitis—Vincristine—colon cancer	0.000158	0.00223	CcSEcCtD
Ezetimibe—Headache—Vincristine—colon cancer	0.000157	0.00221	CcSEcCtD
Ezetimibe—Angiopathy—Methotrexate—colon cancer	0.000155	0.00219	CcSEcCtD
Ezetimibe—Vomiting—Irinotecan—colon cancer	0.000155	0.00219	CcSEcCtD
Ezetimibe—Immune system disorder—Methotrexate—colon cancer	0.000155	0.00218	CcSEcCtD
Ezetimibe—Dizziness—Fluorouracil—colon cancer	0.000155	0.00218	CcSEcCtD
Ezetimibe—Mediastinal disorder—Methotrexate—colon cancer	0.000154	0.00217	CcSEcCtD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000154	0.00329	CbGpPWpGaD
Ezetimibe—Rash—Irinotecan—colon cancer	0.000154	0.00217	CcSEcCtD
Ezetimibe—Dermatitis—Irinotecan—colon cancer	0.000154	0.00217	CcSEcCtD
Ezetimibe—Headache—Irinotecan—colon cancer	0.000153	0.00216	CcSEcCtD
Ezetimibe—Alopecia—Methotrexate—colon cancer	0.000151	0.00213	CcSEcCtD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000151	0.00322	CbGpPWpGaD
Ezetimibe—ABCB1—bone marrow—colon cancer	0.000151	0.0015	CbGeAlD
Ezetimibe—Mental disorder—Methotrexate—colon cancer	0.00015	0.00211	CcSEcCtD
Ezetimibe—Malnutrition—Methotrexate—colon cancer	0.000149	0.0021	CcSEcCtD
Ezetimibe—Erythema—Methotrexate—colon cancer	0.000149	0.0021	CcSEcCtD
Ezetimibe—Nausea—Vincristine—colon cancer	0.000149	0.0021	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000149	0.0021	CcSEcCtD
Ezetimibe—Vomiting—Fluorouracil—colon cancer	0.000149	0.0021	CcSEcCtD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000148	0.00316	CbGpPWpGaD
Ezetimibe—Insomnia—Capecitabine—colon cancer	0.000148	0.00208	CcSEcCtD
Ezetimibe—Rash—Fluorouracil—colon cancer	0.000148	0.00208	CcSEcCtD
Ezetimibe—Dermatitis—Fluorouracil—colon cancer	0.000147	0.00208	CcSEcCtD
Ezetimibe—Paraesthesia—Capecitabine—colon cancer	0.000147	0.00207	CcSEcCtD
Ezetimibe—Headache—Fluorouracil—colon cancer	0.000147	0.00206	CcSEcCtD
Ezetimibe—Dyspnoea—Capecitabine—colon cancer	0.000146	0.00205	CcSEcCtD
Ezetimibe—Nausea—Irinotecan—colon cancer	0.000145	0.00204	CcSEcCtD
Ezetimibe—UGT1A3—Metabolism—CA7—colon cancer	0.000145	0.00309	CbGpPWpGaD
Ezetimibe—ABCB1—vagina—colon cancer	0.000144	0.00144	CbGeAlD
Ezetimibe—Back pain—Methotrexate—colon cancer	0.000144	0.00203	CcSEcCtD
Ezetimibe—Dyspepsia—Capecitabine—colon cancer	0.000144	0.00203	CcSEcCtD
Ezetimibe—CYP3A4—Irinotecan Pathway—APC—colon cancer	0.000142	0.00303	CbGpPWpGaD
Ezetimibe—Decreased appetite—Capecitabine—colon cancer	0.000142	0.002	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Capecitabine—colon cancer	0.000141	0.00199	CcSEcCtD
Ezetimibe—Fatigue—Capecitabine—colon cancer	0.000141	0.00199	CcSEcCtD
Ezetimibe—ABCC3—Fluoropyrimidine Activity—TP53—colon cancer	0.000141	0.003	CbGpPWpGaD
Ezetimibe—Pain—Capecitabine—colon cancer	0.00014	0.00197	CcSEcCtD
Ezetimibe—Constipation—Capecitabine—colon cancer	0.00014	0.00197	CcSEcCtD
Ezetimibe—Nausea—Fluorouracil—colon cancer	0.000139	0.00196	CcSEcCtD
Ezetimibe—Ill-defined disorder—Methotrexate—colon cancer	0.000138	0.00195	CcSEcCtD
Ezetimibe—Anaemia—Methotrexate—colon cancer	0.000138	0.00194	CcSEcCtD
Ezetimibe—Feeling abnormal—Capecitabine—colon cancer	0.000135	0.0019	CcSEcCtD
Ezetimibe—Malaise—Methotrexate—colon cancer	0.000134	0.00189	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Capecitabine—colon cancer	0.000134	0.00188	CcSEcCtD
Ezetimibe—ABCG2—HIF-2-alpha transcription factor network—EP300—colon cancer	0.000132	0.00282	CbGpPWpGaD
Ezetimibe—Cough—Methotrexate—colon cancer	0.00013	0.00183	CcSEcCtD
Ezetimibe—Urticaria—Capecitabine—colon cancer	0.00013	0.00183	CcSEcCtD
Ezetimibe—Body temperature increased—Capecitabine—colon cancer	0.000129	0.00182	CcSEcCtD
Ezetimibe—Abdominal pain—Capecitabine—colon cancer	0.000129	0.00182	CcSEcCtD
Ezetimibe—Arthralgia—Methotrexate—colon cancer	0.000127	0.00179	CcSEcCtD
Ezetimibe—Myalgia—Methotrexate—colon cancer	0.000127	0.00179	CcSEcCtD
Ezetimibe—Chest pain—Methotrexate—colon cancer	0.000127	0.00179	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000126	0.00178	CcSEcCtD
Ezetimibe—ABCG2—HIF-2-alpha transcription factor network—VEGFA—colon cancer	0.000125	0.00267	CbGpPWpGaD
Ezetimibe—Discomfort—Methotrexate—colon cancer	0.000125	0.00177	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000125	0.00266	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CA7—colon cancer	0.000123	0.00263	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CA7—colon cancer	0.000123	0.00263	CbGpPWpGaD
Ezetimibe—Confusional state—Methotrexate—colon cancer	0.000123	0.00173	CcSEcCtD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000123	0.00261	CbGpPWpGaD
Ezetimibe—ABCB1—liver—colon cancer	0.000122	0.00121	CbGeAlD
Ezetimibe—Anaphylactic shock—Methotrexate—colon cancer	0.000122	0.00171	CcSEcCtD
Ezetimibe—Infection—Methotrexate—colon cancer	0.000121	0.0017	CcSEcCtD
Ezetimibe—Hypersensitivity—Capecitabine—colon cancer	0.00012	0.0017	CcSEcCtD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.00012	0.00256	CbGpPWpGaD
Ezetimibe—Nervous system disorder—Methotrexate—colon cancer	0.000119	0.00168	CcSEcCtD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000119	0.00254	CbGpPWpGaD
Ezetimibe—Thrombocytopenia—Methotrexate—colon cancer	0.000119	0.00168	CcSEcCtD
Ezetimibe—Skin disorder—Methotrexate—colon cancer	0.000118	0.00167	CcSEcCtD
Ezetimibe—Asthenia—Capecitabine—colon cancer	0.000117	0.00165	CcSEcCtD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000116	0.00246	CbGpPWpGaD
Ezetimibe—Pruritus—Capecitabine—colon cancer	0.000116	0.00163	CcSEcCtD
Ezetimibe—Diarrhoea—Capecitabine—colon cancer	0.000112	0.00158	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000111	0.00156	CcSEcCtD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.00011	0.00235	CbGpPWpGaD
Ezetimibe—Insomnia—Methotrexate—colon cancer	0.00011	0.00155	CcSEcCtD
Ezetimibe—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000109	0.00233	CbGpPWpGaD
Ezetimibe—Paraesthesia—Methotrexate—colon cancer	0.000109	0.00154	CcSEcCtD
Ezetimibe—Dyspnoea—Methotrexate—colon cancer	0.000109	0.00153	CcSEcCtD
Ezetimibe—Dizziness—Capecitabine—colon cancer	0.000108	0.00152	CcSEcCtD
Ezetimibe—Dyspepsia—Methotrexate—colon cancer	0.000107	0.00151	CcSEcCtD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000107	0.00227	CbGpPWpGaD
Ezetimibe—Decreased appetite—Methotrexate—colon cancer	0.000106	0.00149	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Methotrexate—colon cancer	0.000105	0.00148	CcSEcCtD
Ezetimibe—Fatigue—Methotrexate—colon cancer	0.000105	0.00148	CcSEcCtD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000105	0.00223	CbGpPWpGaD
Ezetimibe—Pain—Methotrexate—colon cancer	0.000104	0.00147	CcSEcCtD
Ezetimibe—Vomiting—Capecitabine—colon cancer	0.000104	0.00146	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—EP300—colon cancer	0.000104	0.00221	CbGpPWpGaD
Ezetimibe—Rash—Capecitabine—colon cancer	0.000103	0.00145	CcSEcCtD
Ezetimibe—Dermatitis—Capecitabine—colon cancer	0.000103	0.00145	CcSEcCtD
Ezetimibe—Headache—Capecitabine—colon cancer	0.000102	0.00144	CcSEcCtD
Ezetimibe—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000102	0.00217	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—ABCB1—colon cancer	0.000102	0.00216	CbGpPWpGaD
Ezetimibe—Feeling abnormal—Methotrexate—colon cancer	0.0001	0.00141	CcSEcCtD
Ezetimibe—UGT1A1—Metabolism—CA7—colon cancer	0.0001	0.00213	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—TYMS—colon cancer	9.97e-05	0.00212	CbGpPWpGaD
Ezetimibe—Gastrointestinal pain—Methotrexate—colon cancer	9.95e-05	0.0014	CcSEcCtD
Ezetimibe—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	9.89e-05	0.00211	CbGpPWpGaD
Ezetimibe—Nausea—Capecitabine—colon cancer	9.71e-05	0.00137	CcSEcCtD
Ezetimibe—ABCG2—Fluoropyrimidine Activity—TP53—colon cancer	9.71e-05	0.00207	CbGpPWpGaD
Ezetimibe—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	9.7e-05	0.00207	CbGpPWpGaD
Ezetimibe—Urticaria—Methotrexate—colon cancer	9.67e-05	0.00136	CcSEcCtD
Ezetimibe—Body temperature increased—Methotrexate—colon cancer	9.62e-05	0.00136	CcSEcCtD
Ezetimibe—Abdominal pain—Methotrexate—colon cancer	9.62e-05	0.00136	CcSEcCtD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	9.46e-05	0.00201	CbGpPWpGaD
Ezetimibe—ABCB1—lymph node—colon cancer	9.34e-05	0.000931	CbGeAlD
Ezetimibe—SLCO1B1—Metabolism—CA7—colon cancer	9.18e-05	0.00196	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	9.1e-05	0.00194	CbGpPWpGaD
Ezetimibe—Hypersensitivity—Methotrexate—colon cancer	8.97e-05	0.00126	CcSEcCtD
Ezetimibe—UGT1A3—Metabolism—CHST5—colon cancer	8.78e-05	0.00187	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—ODC1—colon cancer	8.78e-05	0.00187	CbGpPWpGaD
Ezetimibe—Asthenia—Methotrexate—colon cancer	8.73e-05	0.00123	CcSEcCtD
Ezetimibe—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	8.62e-05	0.00184	CbGpPWpGaD
Ezetimibe—Pruritus—Methotrexate—colon cancer	8.61e-05	0.00121	CcSEcCtD
Ezetimibe—ABCG2—Metabolism—CA7—colon cancer	8.5e-05	0.00181	CbGpPWpGaD
Ezetimibe—Diarrhoea—Methotrexate—colon cancer	8.33e-05	0.00117	CcSEcCtD
Ezetimibe—Dizziness—Methotrexate—colon cancer	8.05e-05	0.00113	CcSEcCtD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.86e-05	0.00168	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—EP300—colon cancer	7.79e-05	0.00166	CbGpPWpGaD
Ezetimibe—Vomiting—Methotrexate—colon cancer	7.74e-05	0.00109	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—ABCB1—colon cancer	7.69e-05	0.00164	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.68e-05	0.00164	CbGpPWpGaD
Ezetimibe—Rash—Methotrexate—colon cancer	7.67e-05	0.00108	CcSEcCtD
Ezetimibe—Dermatitis—Methotrexate—colon cancer	7.67e-05	0.00108	CcSEcCtD
Ezetimibe—Headache—Methotrexate—colon cancer	7.63e-05	0.00107	CcSEcCtD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.57e-05	0.00161	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—TYMS—colon cancer	7.56e-05	0.00161	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	7.53e-05	0.0016	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—ODC1—colon cancer	7.47e-05	0.00159	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CHST5—colon cancer	7.47e-05	0.00159	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—ODC1—colon cancer	7.47e-05	0.00159	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CHST5—colon cancer	7.47e-05	0.00159	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—ABCB1—colon cancer	7.41e-05	0.00158	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—VEGFA—colon cancer	7.38e-05	0.00157	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—TYMS—colon cancer	7.27e-05	0.00155	CbGpPWpGaD
Ezetimibe—Nausea—Methotrexate—colon cancer	7.23e-05	0.00102	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—PPARG—colon cancer	7.06e-05	0.0015	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—CTNNB1—colon cancer	6.8e-05	0.00145	CbGpPWpGaD
Ezetimibe—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	6.75e-05	0.00144	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	6.34e-05	0.00135	CbGpPWpGaD
Ezetimibe—UGT1A3—NRF2 pathway—TGFB1—colon cancer	6.12e-05	0.0013	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CHST5—colon cancer	6.07e-05	0.00129	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—ODC1—colon cancer	6.07e-05	0.00129	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.82e-05	0.00124	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.6e-05	0.00119	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—ODC1—colon cancer	5.56e-05	0.00118	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CHST5—colon cancer	5.56e-05	0.00118	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—PTGS2—colon cancer	5.56e-05	0.00118	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PPARG—colon cancer	5.35e-05	0.00114	CbGpPWpGaD
Ezetimibe—UGT2B7—NRF2 pathway—TGFB1—colon cancer	5.21e-05	0.00111	CbGpPWpGaD
Ezetimibe—ABCC3—NRF2 pathway—TGFB1—colon cancer	5.21e-05	0.00111	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PPARG—colon cancer	5.15e-05	0.0011	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—ODC1—colon cancer	5.15e-05	0.0011	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CHST5—colon cancer	5.15e-05	0.0011	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	5.07e-05	0.00108	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—AKT1—colon cancer	4.71e-05	0.001	CbGpPWpGaD
Ezetimibe—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	4.66e-05	0.000993	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—EP300—colon cancer	4.62e-05	0.000984	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CA7—colon cancer	4.6e-05	0.000979	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—ABCB1—colon cancer	4.33e-05	0.000923	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—TYMS—colon cancer	4.26e-05	0.000907	CbGpPWpGaD
Ezetimibe—UGT1A1—NRF2 pathway—TGFB1—colon cancer	4.23e-05	0.000901	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—ABCB1—colon cancer	4.21e-05	0.000898	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	4.21e-05	0.000898	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PTGS2—colon cancer	4.21e-05	0.000897	CbGpPWpGaD
Ezetimibe—ABCC2—NRF2 pathway—TGFB1—colon cancer	4.13e-05	0.000879	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CASP3—colon cancer	4.07e-05	0.000868	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PTGS2—colon cancer	4.05e-05	0.000863	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	3.99e-05	0.00085	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	3.89e-05	0.000828	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	3.74e-05	0.000797	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—EP300—colon cancer	3.5e-05	0.000746	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—VEGFA—colon cancer	3.46e-05	0.000736	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—PIK3CA—colon cancer	3.42e-05	0.000728	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—EP300—colon cancer	3.37e-05	0.000718	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—ABCB1—colon cancer	3.34e-05	0.000712	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—TGFB1—colon cancer	3.17e-05	0.000676	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—ABCB1—colon cancer	3.14e-05	0.000668	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.08e-05	0.000657	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PPARG—colon cancer	3.01e-05	0.000642	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—ABCB1—colon cancer	2.91e-05	0.000619	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	2.85e-05	0.000608	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CA7—colon cancer	2.83e-05	0.000603	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—AKT1—colon cancer	2.79e-05	0.000595	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—ODC1—colon cancer	2.78e-05	0.000593	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CHST5—colon cancer	2.78e-05	0.000593	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PIK3CA—colon cancer	2.59e-05	0.000552	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	2.55e-05	0.000542	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PIK3CA—colon cancer	2.49e-05	0.000531	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.43e-05	0.000517	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PTGS2—colon cancer	2.37e-05	0.000505	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—ABCB1—colon cancer	2.32e-05	0.000494	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.3e-05	0.000489	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—TYMS—colon cancer	2.28e-05	0.000486	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.17e-05	0.000461	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—AKT1—colon cancer	2.12e-05	0.000451	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—AKT1—colon cancer	2.04e-05	0.000434	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.02e-05	0.00043	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.01e-05	0.000428	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—ABCB1—colon cancer	1.97e-05	0.00042	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—ABCB1—colon cancer	1.97e-05	0.00042	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—EP300—colon cancer	1.97e-05	0.00042	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	1.96e-05	0.000417	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—TYMS—colon cancer	1.94e-05	0.000413	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—TYMS—colon cancer	1.94e-05	0.000413	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	1.94e-05	0.000413	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.89e-05	0.000403	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.81e-05	0.000385	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.8e-05	0.000384	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.75e-05	0.000373	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CHST5—colon cancer	1.72e-05	0.000365	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—ODC1—colon cancer	1.72e-05	0.000365	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.71e-05	0.000363	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PPARG—colon cancer	1.61e-05	0.000344	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—ABCB1—colon cancer	1.6e-05	0.000342	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—TYMS—colon cancer	1.58e-05	0.000336	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.57e-05	0.000334	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.57e-05	0.000333	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.53e-05	0.000327	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.5e-05	0.00032	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.49e-05	0.000318	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—ABCB1—colon cancer	1.47e-05	0.000313	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PIK3CA—colon cancer	1.46e-05	0.000311	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.45e-05	0.000309	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—TYMS—colon cancer	1.44e-05	0.000307	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PPARG—colon cancer	1.37e-05	0.000293	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PPARG—colon cancer	1.37e-05	0.000293	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—ABCB1—colon cancer	1.36e-05	0.00029	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—TYMS—colon cancer	1.34e-05	0.000285	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.33e-05	0.000284	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.29e-05	0.000275	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PTGS2—colon cancer	1.27e-05	0.000271	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—AKT1—colon cancer	1.19e-05	0.000254	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PPARG—colon cancer	1.12e-05	0.000238	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.11e-05	0.000237	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.09e-05	0.000232	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PTGS2—colon cancer	1.08e-05	0.00023	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PTGS2—colon cancer	1.08e-05	0.00023	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—EP300—colon cancer	1.06e-05	0.000225	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PPARG—colon cancer	1.02e-05	0.000218	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PPARG—colon cancer	9.47e-06	0.000202	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—EP300—colon cancer	8.98e-06	0.000191	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—EP300—colon cancer	8.98e-06	0.000191	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PTGS2—colon cancer	8.78e-06	0.000187	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PTGS2—colon cancer	8.04e-06	0.000171	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PIK3CA—colon cancer	7.82e-06	0.000166	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PTGS2—colon cancer	7.45e-06	0.000159	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—EP300—colon cancer	7.3e-06	0.000156	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—TYMS—colon cancer	7.23e-06	0.000154	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—EP300—colon cancer	6.69e-06	0.000143	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PIK3CA—colon cancer	6.65e-06	0.000142	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PIK3CA—colon cancer	6.65e-06	0.000142	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—AKT1—colon cancer	6.39e-06	0.000136	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—EP300—colon cancer	6.19e-06	0.000132	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—AKT1—colon cancer	5.43e-06	0.000116	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—AKT1—colon cancer	5.43e-06	0.000116	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PIK3CA—colon cancer	5.4e-06	0.000115	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PPARG—colon cancer	5.12e-06	0.000109	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PIK3CA—colon cancer	4.95e-06	0.000105	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PIK3CA—colon cancer	4.58e-06	9.76e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—ABCB1—colon cancer	4.53e-06	9.66e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—TYMS—colon cancer	4.45e-06	9.48e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—AKT1—colon cancer	4.41e-06	9.4e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—AKT1—colon cancer	4.04e-06	8.61e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PTGS2—colon cancer	4.03e-06	8.58e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—AKT1—colon cancer	3.74e-06	7.97e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—EP300—colon cancer	3.35e-06	7.13e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PPARG—colon cancer	3.15e-06	6.72e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PTGS2—colon cancer	2.48e-06	5.28e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PIK3CA—colon cancer	2.48e-06	5.28e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—EP300—colon cancer	2.06e-06	4.4e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—AKT1—colon cancer	2.02e-06	4.31e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PIK3CA—colon cancer	1.53e-06	3.25e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—AKT1—colon cancer	1.25e-06	2.66e-05	CbGpPWpGaD
